Divalproex Sodium Capsule, Coated Pellets
NDC Package 27241-115-01

11-digit billing NDC: 27241011501

Package Information

Divalproex Sodium capsules is divalproex sodium delayed-release capsules is contraindicated in patients:with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. This formulation utilizes a capsule, coated pellets delivery system. Marketed by Ajanta Pharma Usa Inc., this product is identified by NDC 27241-115 and is authorized under FDA application ANDA213181.

Identification & Billing

NDC Package Code
27241-115-01
Package Description
100 CAPSULE, COATED PELLETS in 1 BOTTLE
Product Code
11-Digit Billing Format
27241011501
RxNorm Crosswalk
RxCUI: 1099596 - divalproex sodium 125 MG Delayed Release Oral Capsule

Clinical Specifications

Proprietary Name
Divalproex Sodium
Non-Proprietary Name
Divalproex Sodium
Substance Name
Divalproex Sodium
Dosage Form
Capsule, Coated Pellets - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Divalproex sodium delayed-release capsules is contraindicated in patients:with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions (5.12, 5.13, 5.14)].with known urea cycle disorders [see Warnings and Precautions (5.6)].being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)].

Regulatory & Marketing

Labeler Name
Ajanta Pharma Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA213181
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-15-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (27241-115). Click a package code to view its specific billing and regulatory data.

500 CAPSULE, COATED PELLETS in 1 BOTTLE
1000 CAPSULE, COATED PELLETS in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 27241-115-01 identifies a specific commercial package of 100 capsule, coated pellets in 1 bottle of Divalproex Sodium, a human prescription drug labeled by Ajanta Pharma Usa Inc.. This capsule, coated pellets is formulated for oral use and contains divalproex sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ajanta Pharma Usa Inc. on May 15, 2020. The current certification is valid through December 31, 2027.

How is this Ajanta Pharma Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 27241011501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
27241-115-01
11-Digit CMS (5-4-2)
27241-0115-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.